Charlotte's Web (CWBHF) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
13 May, 2026Executive summary
Q1 2026 revenue was $11.2 million, down 9% year-over-year, mainly due to retail channel restructuring and a shift to a margin-accretive distributor model.
Net loss widened to $13.1 million ($0.08/share), compared to $6.2 million ($0.04/share) in Q1 2025, driven by a significant non-cash loss on financial instruments.
Announced a proposed transaction with BAT to convert a C$75.3 million ($54M) debenture and invest an additional $10 million in equity, eliminating ~$65 million in debt and reducing annual interest costs by $3 million, pending shareholder and TSX approval.
CMS activated the BEI program, enabling eligible hemp-derived CBD products to be covered for select Medicare/Medicaid beneficiaries.
Focused on advancing medical and healthcare-practitioner channels, expanding product portfolio, and launching a practitioner portal.
Financial highlights
Total assets at March 31, 2026 were $70.7 million, down from $75.3 million at year-end 2025.
Cash and cash equivalents were $5.2 million at quarter-end, down from $8.0 million at December 31, 2025 and $19.4 million a year ago.
SG&A expenses declined 17.7% year-over-year to $9.5 million, reflecting cost optimization and exit from the MLB agreement.
Net cash used in operating activities was $2.8 million, nearly flat year-over-year.
Convertible debenture principal was $63.8 million, with a net carrying amount of $51.5 million.
Outlook and guidance
Management expects gross margin to trend toward 50% as in-house production efficiencies scale and transitional costs normalize.
SG&A is expected to remain around $10 million per quarter, reflecting a leaner cost base and continued cost containment.
Liquidity is expected to strengthen significantly upon completion of the BAT transaction, with sufficient cash to fund operations for the next 12 months.
Long-term liquidity will depend on revenue growth, expense management, and successful completion of the BAT transaction.
Early phase of BEI program is implementation-led, with adoption visibility expected in the second half of 2026.
Latest events from Charlotte's Web
- Returned to growth as the #1 CBD brand, leveraging innovation, partnerships, and regulatory momentum.CWBHF
Investor presentation26 Apr 2026 - Shareholders to vote on BAT transaction, director elections, and key governance matters.CWBHF
Proxy filing16 Apr 2026 - Key votes include director elections and a debenture amendment that may shift company control.CWBHF
Proxy filing16 Apr 2026 - Shareholders to vote on BAT's conversion to a control person, reshaping ownership and governance.CWBHF
Proxy filing6 Apr 2026 - BAT's investment and debenture conversion will give it 40.8% ownership and expanded governance rights.CWBHF
Proxy filing1 Apr 2026 - Debt eliminated, revenue up, and new capital positions for Medicare-driven growth.CWBHF
Q4 202531 Mar 2026 - BAT transaction and regulatory momentum drive financial and strategic transformation.CWBHF
Proxy filing31 Mar 2026 - BAT's conversion and $10M investment will eliminate $65M debt and give it 40% ownership.CWBHF
Proxy filing31 Mar 2026 - Sequential revenue growth and cost cuts support breakeven and turnaround progress.CWBHF
Q2 20242 Feb 2026